Global Blood Therapeutics Leaves ASH With Momentum Behind Voxelotor In Sickle Cell Disease

 
• By Jessica Merrill

Company revealed that US FDA agreed to accelerated approval pathway for voxelotor in sickle cell disease, with focus on stroke prevention. Updated data from a key trial was also released at ASH.

Anemia, sickle cell and normal red blood cell, 3d Illustration.

More from Clinical Trials

More from R&D